reports
Total number of shares and voting rights in Zealand Pharma as of June ...
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar mo...
- ING Helpdesk
- Hans D’Haese
- Maxime Stranart
Colruyt/Divestment of loss-making French activity/BUY
We reiterate our BUY on Colruyt but reduce our target price from €45.5 to €44 following Colruyt's FY24/25 results. We believe that the competitive environment should improve for Colruyt in the upcoming months, noting (1) we lap tough comps on competitors opening stores on Sundays; (2) Colruyt will open its 146 OKay stores on Sunday as of early 2026, thanks to a change in Belgian regulation; and (3) reduced GDP growth forecasts in Belgium, which should benefit discounters. Valuation remains undem...
Colruyt Group N.V: 1 director
A director at Colruyt Group N.V bought 10,750 shares at 36.900EUR and the significance rating of the trade was 90/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Jacob Mekhael
ADA amylin monotherapy highlights Zealand, Novo, Lilly
The American Diabetes Association (ADA) conference was held 20-23 June, 2025 and contained a number of highly anticipated updates in the obesity pipeline. We summarise the key amylin monotherapy datasets in this note including data from Zealand from petrelintide's phase 1b showing higher weight loss in females, Lilly's eloralintide full presentation, which shows that the higher doses which showed competitive weight loss and generated excitement following the abstract release also come with heada...
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Wim Lewi
- Michiel Declercq
Colruyt On the right track, but challenges remain
Last week, Colruyt published its FY24/25 results. While the results were in line with expectations, the outlook disappointed on the back of a challenging competitive environment. Despite the ongoing difficulties, we welcome the recently signed agreement to divest around 80% of its French stores. We expect that a full exit from the French market will enhance margins by around 40–50 basis points in FY26/27. Additionally, the transaction multiple is in line with market valuations. Incorporating the...
Aalberts reports the progress of its share buyback programme 16 June ...
Aalberts reports the progress of its share buyback programme 16 June – 20 June 2025 Aalberts today reports that it has repurchased 99,111 of its own shares in the period from 16 June 2025, up to and including 20 June 2025, for an amount of EUR 2,939,682.20, so at an average share price of EUR 29.66. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancelled following repurchase....
- Jean Danjou
- Jean Danjou
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Jacob Mekhael
Zealand Pharma We think sell off is overdone, jury is still out on elo...
Following the release of phase 1 MAD results for eloralintide (Lilly, no coverage) showing 11.3% weight loss at 12 weeks, Zealand's stock has declined -18% over the last 5 days. While the results look competitive vs. Zealand's petrelintide at first glance, key details on dosing and GI side effects per treatment arm remain undisclosed. We note that, given their similar activity on both amylin and calcitonin receptors, cagrilintide's long term 68 week data de-risks petrelintide's development. This...
- Robert Jan Vos
- Jacob Mekhael
Zealand Pharma Dapiglutide phase 1b shows strong weight loss, plans to...
Zealand announced topline results from part 2 of the phase 1b multiple ascending dose (MAD) trial of dapiglutide (long-acting GLP-1/GLP-2 receptor dual agonist) in overweight/obese participants, which showed 11.4% (placebo adjusted) weight loss, coming in higher than semaglutide, and closer to tirzepatide at a similar timepoint in the phase 3 (STEP-1 and SURMOUNT-1) trials. By targeting GLP-2 on top of GLP-1, dapiglutide aims to address low grade inflammation on top of weight loss. As such, we b...
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Zealand Pharma announces positive topline results from 28-week Phase 1...
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal a...
- Michiel Declercq
- Michiel Declercq
Colruyt FY24/25 results in line, reaches agreement for most of its Fre...
Despite only being expected after market, Colruyt already published its FY24/25 results this morning. Overall, the FY24/25 results were in line with our expectations after the group issued a profit warning early May. In FY24/25, group sales increased 1.1% but declined 0.4% on a comparable basis to € 10963m (kbcse: € 10999m) while the EBIT decreased by 5.0% to € 446m (kbcse: € 448m). Additionally, the group announced that it has reached an agreement to sell 81 of French stores for a cash consider...
- ING Helpdesk
Aalberts reports the progress of its share buyback programme 09 June -...
Aalberts reports the progress of its share buyback programme 09 June - 13 June 2025 Aalberts today reports that it has repurchased 2,500 of its own shares in the period from 09 June 2025, up to and including 13 June 2025, for an amount of EUR 78,285.24, so at an average share price of EUR 31.31. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancelled following repurchase. Up ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.